Ge Long Hui·2025-10-29 05:12Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone in its product development [1] Group 1: Product Approval - The sustained-release tablet of Bromidespasm has been granted a drug registration certificate by the National Medical Products Administration [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - Shanghai Pharmaceuticals submitted the registration application for this drug in March 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 16.09 million in research and development for this drug as of the date of the announcement [1]